We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Clinical track: Urology-non-prostate
Poster
Clinical
00:00 - 00:00
Immune response gene expression analysis and response to radical chemoradiation in bladder cancer
PO-1206
00:00 - 00:00
Exploring molecular subtype as a biomarker of radiation response in muscle-invasive bladder cancer
PO-1207
00:00 - 00:00
Small cell carcinoma of the bladder: Retrospective long-term outcomes of chemoradiation
PO-1205
00:00 - 00:00
Impact of bladder size at radiotherapy planning scan on survival
PO-1215
00:00 - 00:00
Can sarcopenia predict outcomes in bladder cancer patients treated with chemoradiotherapy?
PO-1216
00:00 - 00:00
Safety of Nivolumab and stereotactic RT in metastatic renal carcinoma: early results of NIVES study
PO-1217
00:00 - 00:00
A novel liquid fiducial marker for image-guided adaptive radiotherapy in bladder cancer.
PO-1209
00:00 - 00:00
Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?
PO-1218
00:00 - 00:00
Primary Bladder Sarcoma: a multi-institutional experience from the Rare Cancer Network.
PO-1219
00:00 - 00:00
Organ-preserving treatment for muscle-invasive bladder cancer: outcomes and prognostic factors
PO-1220
00:00 - 00:00
Dose-volume predictors of distal urethral toxicity after PDR brachytherapy for penile carcinoma
PO-1221
00:00 - 00:00
Local treatment on the outcome of immune-checkpoint inhibitors in metastatic urothelial carcinoma
PO-1210
00:00 - 00:00
Stereotactic radiotherapy combined with immune- or targeted therapy for renal cell cancer patients.
PO-1211
00:00 - 00:00
High-dose rate brachytherapy in the treatment of early stages of penile carcinoma
PO-1208
00:00 - 00:00
SBRT in patients with oligometastatic renal cell carcinoma in the era of immunotherapy
PO-1212
00:00 - 00:00
Pelvic radiotherapy in node positive bladder cancer – outcomes in a selected cohort
PO-1213
00:00 - 00:00
Stereotactic Body Radiation Therapy in the management of oligometastases from urothelial cancer.
PO-1214